Premium
CLINICAL ACTIVITY OF LONCASTUXIMAB TESIRINE PLUS IBRUTINIB IN NON‐HODGKIN LYMPHOMA: UPDATED LOTIS 3 PHASE 1 RESULTS
Author(s) -
Depaus J,
WagnerJohnston N,
Zinzani P. L,
Phillips T. J,
Maly J,
Ferrari S,
Bachy E,
Bryan L. J,
Delwail V,
Janakiram M,
de Guibert S,
Tani M,
Dai V,
Havenith K,
Boni J,
He X,
ErvinHaynes A,
CarloStella C
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.150_2880
Subject(s) - ibrutinib , medicine , tolerability , mantle cell lymphoma , lymphoma , oncology , phases of clinical research , regimen , pharmacology , adverse effect , chemotherapy , leukemia , chronic lymphocytic leukemia